Daxor Corp (DXR) 7.07 $DXR
Daxor to Explore Possible Partnership or Partial Sale of the Company
Marketwire - Thu Jun 19, 8:30AM CDT
Daxor Corporation (NYSE MKT: DXR) -- The Board of Directors of Daxor Corporation, at its June 18, 2014 meeting, renewed its annual stock buy-back program of up 250,000 shares.
Heart Failure Study From the Mayo Clinic Utilizing Daxor's BVA-100 Blood Volume Analyzer Published in Journal of the American College of Cardiology - Heart Failure
Marketwire - Fri May 30, 7:30AM CDT
Daxor Corporation (NYSE MKT: DXR) -- The Journal of the American College of Cardiology - Heart Failure has published the first study measuring congestive heart failure patients' blood volumes at the initiation of treatment and just prior to discharge. The authors were Wayne L. Miller, MD, PhD, and Brian P. Mullan, MD. The Mayo Clinic's cardiology department is ranked #2 in the annual survey of U.S. hospitals for 2013 - 2014 according to the U.S. News and World Report.
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2013
Marketwire - Fri Feb 28, 7:30AM CST
Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of December 31, 2013. Copies of the form will be mailed to the Company's shareholders and are available on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-12312013.pdf.
Daxor Corporation Announces Dr. Joseph Feldschuh, President and CEO, Sustained a Fractured Hip, Had Emergency Surgery, and Received a Transfusion of His Own Frozen Blood Which Had Been Stored Four Years Ago
Marketwire - Tue Feb 11, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced that its President and Chief Executive Officer, Dr. Joseph Feldschuh, fractured his hip on February 4, 2014 when he slipped on black ice outside his house.
Daxor Announces a Research Study That Proves Micro Samples Are Feasible for Accurate Blood Volume Measurements on Infants and Small Children Utilizing the BVA-100 Blood Volume Analyzer
Marketwire - Wed Jan 15, 7:30AM CST
Daxor Corporation, (NYSE MKT: DXR)
/ CORRECTION - Classic Textbook on Critical Care, the ICU book by Paul Marino, M.D., PhD., Recommends Direct Measurement of Blood Volume in Evaluating Critically Ill Patients
Marketwire - Tue Jan 07, 1:28PM CST
In the news release, "Classic Textbook on Critical Care, the ICU book by Paul Marino, M.D., PhD., Recommends Direct Measurement of Blood Volume in Evaluating Critically Ill Patients," issued earlier today by Daxor Corporation (NYSE MKT: DXR), we are advised by the company that the last sentence of the second paragraph should read "8% death rate vs. a 24% death rate" rather than "8% survival rate vs. a 20% death rate" as originally issued. Complete corrected text follows.
Classic Textbook on Critical Care, the ICU book by Paul Marino, M.D., PhD., Recommends Direct Measurement of Blood Volume in Evaluating Critically Ill Patients
Marketwire - Tue Jan 07, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR)
Daxor Corporation Announces Filing of Form N-CSR for June 30, 2013
Marketwire - Fri Aug 23, 7:30AM CDT
Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR later today disclosing its schedule of portfolio holdings as of June 30, 2013. Copies of the form will be mailed to the Company's shareholders and will also be available on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-06302013.pdf.
Daxor Corporation Announces Receipt of Blood Banking Contract From Prestigious Law Firm Stroock & Stroock & Lavan LLP
Marketwire - Wed Aug 07, 7:31AM CDT
Idant Laboratories, a subsidiary of the medical instrumentation and biotechnology company Daxor Corporation (NYSE MKT: DXR), today announced that it received a blood banking contract from Stroock & Stroock & Lavan LLP. The contract provides for eligible employees of Stroock & Stroock & Lavan LLP to store their own (autologous) frozen blood for future use.
Daxor Corporation Announces Publication of "Blood Volume Determination, A Nuclear Medicine Test in Evolution"
Marketwire - Thu Jul 11, 7:30AM CDT
Daxor Corporation, (NYSE MKT: DXR) announced today that the July, 2013 issue of the journal Clinical Nuclear Medicine (Vol. 38, #7, p 534-540) has published a review article by Dr. Donald Margouleff, MD, FACP, entitled "Blood Volume Determination, A Nuclear Medicine Test in Evolution". Dr. Margouleff is Board Certified in both Nuclear Medicine and Internal Medicine. He is Chief Emeritus of the Division of Nuclear Medicine Department of Radiology at North Shore University Hospital in Manhasset, New York. He is also a member of the Department of Medicine at the same institution with the academic title of Professor of Clinical Medicine. For over 20 years Dr. Margouleff served as Chairman of the Radiological Health Advisory Committee of the Bureau of Environmental Radiation Protection of the New York State Department of Health. Dr. Margouleff was responsible for introducing the second PET scanner and Cyclotron in New York State, which is used for cancer staging and clinical applications.
Blood Banking And Blood Products: Private Cord Blood Banking - Flying High Despite Opposition - Global Strategic Business Report 2012-2018
M2 - Wed Jun 26, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fwphg4/blood_banking_and) has announced the addition of the "Blood Banking And Blood Products - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Blood Banking and Blood Products in US$ Million by the following Product Segments: Blood Components and Plasma Products (Whole Blood & Cellular Components, & Plasma Fractions), and Equipment, Blood Tests and Other Consumables (Includes blood screening and related QC function, but excludes patient diagnosis). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 232 companies including leading blood banks such as AABB, Americas Blood Centers, American Red Cross, Canadian Blood Services, Japan Red Cross
Daxor Corporation Announces the Bi-Monthly Publication of a Medical Column by Its President, Dr. Joseph Feldschuh
Marketwire - Thu Jun 13, 7:30AM CDT
Daxor Corporation (NYSE MKT: DXR) -- Dr. Joseph Feldschuh, the President, CEO and Chief Scientific Officer of Daxor Corporation, will publish a bi-monthly medical column for internet distribution. This column will be separate from his work for Daxor. The column will focus not only on issues of importance to Daxor such as blood banking and hospitals utilizing blood volume measurement in the treatment of patients, but will also focus on many areas of medicine which are of major importance to consumers.
Daxor Corporation Announces Placement of BVA-100 Blood Volume Analyzer at Austin Nuclear Pharmacy, Inc.
Marketwire - Thu May 16, 7:30AM CDT
Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced today that Austin Nuclear Pharmacy, Inc. has leased a BVA-100 Blood Volume Analyzer.
Heartbeat Clinic in Dallas Acquires Blood Volume Analyzer; Daxor Corporation Announces 250,000 Share Buyback
Marketwire - Thu Mar 21, 7:30AM CDT
Daxor Corporation (NYSE MKT: DXR)
Daxor Corporation Announces the Sale of a BVA-100 Blood Volume Analyzer to Banner Good Samaritan Medical Center of Phoenix, Arizona
Marketwire - Thu Mar 07, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced today that Banner Good Samaritan Medical Center of Phoenix, Arizona has purchased a BVA-100 Blood Volume Analyzer.
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2012 and Volumex Kit Sales for 2012
Marketwire - Fri Mar 01, 7:30AM CST
Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of December 31, 2012. Copies of the form will be mailed to the Company's shareholders and are available on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-12312012.pdf.
Reports of a Study Comparing Daxor's Direct Blood Volume Measurement With a Non-Invasive Hemoglobin Monitor in Critically Ill Surgical Patients
Marketwire - Thu Feb 14, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR)
A Study Evaluating Hyponatremia Utilizing the BVA-100 Is Presented at Annual 2013 Critical Care Congress
Marketwire - Thu Jan 31, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR)
Daxor to Explore Possible Partnership or Partial Sale of the Company
Marketwire - Thu Jun 19, 8:30AM CDT
Daxor Corporation (NYSE MKT: DXR) -- The Board of Directors of Daxor Corporation, at its June 18, 2014 meeting, renewed its annual stock buy-back program of up 250,000 shares.
Heart Failure Study From the Mayo Clinic Utilizing Daxor's BVA-100 Blood Volume Analyzer Published in Journal of the American College of Cardiology - Heart Failure
Marketwire - Fri May 30, 7:30AM CDT
Daxor Corporation (NYSE MKT: DXR) -- The Journal of the American College of Cardiology - Heart Failure has published the first study measuring congestive heart failure patients' blood volumes at the initiation of treatment and just prior to discharge. The authors were Wayne L. Miller, MD, PhD, and Brian P. Mullan, MD. The Mayo Clinic's cardiology department is ranked #2 in the annual survey of U.S. hospitals for 2013 - 2014 according to the U.S. News and World Report.
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2013
Marketwire - Fri Feb 28, 7:30AM CST
Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of December 31, 2013. Copies of the form will be mailed to the Company's shareholders and are available on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-12312013.pdf.
Daxor Corporation Announces Dr. Joseph Feldschuh, President and CEO, Sustained a Fractured Hip, Had Emergency Surgery, and Received a Transfusion of His Own Frozen Blood Which Had Been Stored Four Years Ago
Marketwire - Tue Feb 11, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced that its President and Chief Executive Officer, Dr. Joseph Feldschuh, fractured his hip on February 4, 2014 when he slipped on black ice outside his house.
Daxor Announces a Research Study That Proves Micro Samples Are Feasible for Accurate Blood Volume Measurements on Infants and Small Children Utilizing the BVA-100 Blood Volume Analyzer
Marketwire - Wed Jan 15, 7:30AM CST
Daxor Corporation, (NYSE MKT: DXR)
/ CORRECTION - Classic Textbook on Critical Care, the ICU book by Paul Marino, M.D., PhD., Recommends Direct Measurement of Blood Volume in Evaluating Critically Ill Patients
Marketwire - Tue Jan 07, 1:28PM CST
In the news release, "Classic Textbook on Critical Care, the ICU book by Paul Marino, M.D., PhD., Recommends Direct Measurement of Blood Volume in Evaluating Critically Ill Patients," issued earlier today by Daxor Corporation (NYSE MKT: DXR), we are advised by the company that the last sentence of the second paragraph should read "8% death rate vs. a 24% death rate" rather than "8% survival rate vs. a 20% death rate" as originally issued. Complete corrected text follows.
Classic Textbook on Critical Care, the ICU book by Paul Marino, M.D., PhD., Recommends Direct Measurement of Blood Volume in Evaluating Critically Ill Patients
Marketwire - Tue Jan 07, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR)
Daxor Corporation Announces Filing of Form N-CSR for June 30, 2013
Marketwire - Fri Aug 23, 7:30AM CDT
Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR later today disclosing its schedule of portfolio holdings as of June 30, 2013. Copies of the form will be mailed to the Company's shareholders and will also be available on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-06302013.pdf.
Daxor Corporation Announces Receipt of Blood Banking Contract From Prestigious Law Firm Stroock & Stroock & Lavan LLP
Marketwire - Wed Aug 07, 7:31AM CDT
Idant Laboratories, a subsidiary of the medical instrumentation and biotechnology company Daxor Corporation (NYSE MKT: DXR), today announced that it received a blood banking contract from Stroock & Stroock & Lavan LLP. The contract provides for eligible employees of Stroock & Stroock & Lavan LLP to store their own (autologous) frozen blood for future use.
Daxor Corporation Announces Publication of "Blood Volume Determination, A Nuclear Medicine Test in Evolution"
Marketwire - Thu Jul 11, 7:30AM CDT
Daxor Corporation, (NYSE MKT: DXR) announced today that the July, 2013 issue of the journal Clinical Nuclear Medicine (Vol. 38, #7, p 534-540) has published a review article by Dr. Donald Margouleff, MD, FACP, entitled "Blood Volume Determination, A Nuclear Medicine Test in Evolution". Dr. Margouleff is Board Certified in both Nuclear Medicine and Internal Medicine. He is Chief Emeritus of the Division of Nuclear Medicine Department of Radiology at North Shore University Hospital in Manhasset, New York. He is also a member of the Department of Medicine at the same institution with the academic title of Professor of Clinical Medicine. For over 20 years Dr. Margouleff served as Chairman of the Radiological Health Advisory Committee of the Bureau of Environmental Radiation Protection of the New York State Department of Health. Dr. Margouleff was responsible for introducing the second PET scanner and Cyclotron in New York State, which is used for cancer staging and clinical applications.
Blood Banking And Blood Products: Private Cord Blood Banking - Flying High Despite Opposition - Global Strategic Business Report 2012-2018
M2 - Wed Jun 26, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fwphg4/blood_banking_and) has announced the addition of the "Blood Banking And Blood Products - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Blood Banking and Blood Products in US$ Million by the following Product Segments: Blood Components and Plasma Products (Whole Blood & Cellular Components, & Plasma Fractions), and Equipment, Blood Tests and Other Consumables (Includes blood screening and related QC function, but excludes patient diagnosis). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 232 companies including leading blood banks such as AABB, Americas Blood Centers, American Red Cross, Canadian Blood Services, Japan Red Cross
Daxor Corporation Announces the Bi-Monthly Publication of a Medical Column by Its President, Dr. Joseph Feldschuh
Marketwire - Thu Jun 13, 7:30AM CDT
Daxor Corporation (NYSE MKT: DXR) -- Dr. Joseph Feldschuh, the President, CEO and Chief Scientific Officer of Daxor Corporation, will publish a bi-monthly medical column for internet distribution. This column will be separate from his work for Daxor. The column will focus not only on issues of importance to Daxor such as blood banking and hospitals utilizing blood volume measurement in the treatment of patients, but will also focus on many areas of medicine which are of major importance to consumers.
Daxor Corporation Announces Placement of BVA-100 Blood Volume Analyzer at Austin Nuclear Pharmacy, Inc.
Marketwire - Thu May 16, 7:30AM CDT
Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced today that Austin Nuclear Pharmacy, Inc. has leased a BVA-100 Blood Volume Analyzer.
Heartbeat Clinic in Dallas Acquires Blood Volume Analyzer; Daxor Corporation Announces 250,000 Share Buyback
Marketwire - Thu Mar 21, 7:30AM CDT
Daxor Corporation (NYSE MKT: DXR)
Daxor Corporation Announces the Sale of a BVA-100 Blood Volume Analyzer to Banner Good Samaritan Medical Center of Phoenix, Arizona
Marketwire - Thu Mar 07, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced today that Banner Good Samaritan Medical Center of Phoenix, Arizona has purchased a BVA-100 Blood Volume Analyzer.
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2012 and Volumex Kit Sales for 2012
Marketwire - Fri Mar 01, 7:30AM CST
Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of December 31, 2012. Copies of the form will be mailed to the Company's shareholders and are available on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-12312012.pdf.
Reports of a Study Comparing Daxor's Direct Blood Volume Measurement With a Non-Invasive Hemoglobin Monitor in Critically Ill Surgical Patients
Marketwire - Thu Feb 14, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR)
A Study Evaluating Hyponatremia Utilizing the BVA-100 Is Presented at Annual 2013 Critical Care Congress
Marketwire - Thu Jan 31, 7:30AM CST
Daxor Corporation (NYSE MKT: DXR)
